Lee's Pharmaceutical

Specialty pharma, cardiovascular/respiratory/oncology

0950 · HKEX · Hong Kong

Public Market Listing

0950HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Lee's Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
1Phase 3 / Filed
3Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Loxapine (Adasuve)No recent activity
Phase 3
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder
Phase 2/3
Na-K ATPase / SERCA2aSmall molecule
Heart Failure
Cardiogenic Shock in Acute Heart Failure
rostafuroxinNo recent activity
Phase 2
Endogenous ouabain / mutant adducinSmall molecule
Hypertension
Resistant Hypertension with Adducin/Ouabain Polymorphisms
Preclinical / Unstaged
L-type calcium channels (Cav1.2)Small molecule
Hypertension

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
IstaroximePhase 2/3Cardiogenic Shock
Est. primary completion 2028-12 · NCT07583446 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$89M$5.3M$39M—report ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$184M$14M$45M—report ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$179M$11M$28M—report ↗
2023-FY$135M$12M$22M—report ↗
2022-FY$157M$22M$24M—report ↗
2021-FY$163M$31M$36M—report ↗
2020-FY$157M$26M$48M—report ↗